Ye L - Search Results

1

Immunopontentiating and antitumor activities of a polysaccharide from Pulsatilla chinensis (Bunge) Regel.

Liu T, Ye L, Guan X, Liang X, Li C, Sun Q, Liu Y, Chen S, Bang F, Liu B. Liu T, et al. Among authors: ye l. Int J Biol Macromol. 2013 Mar;54:225-9. doi: 10.1016/j.ijbiomac.2012.12.012. Epub 2012 Dec 12. Int J Biol Macromol. 2013. PMID: 23246414

2

Circulating autoantibody to FOXP3 may be a potential biomarker for esophageal squamous cell carcinoma.

Ye L, Guan S, Zhang C, Lee KH, Sun S, Wei J, Liu B. Ye L, et al. Tumour Biol. 2013 Jun;34(3):1873-7. doi: 10.1007/s13277-013-0729-8. Epub 2013 Mar 13. Tumour Biol. 2013. PMID: 23483489

3

miR-211 promotes non-small cell lung cancer proliferation by targeting SRCIN1.

Ye L, Wang H, Liu B. Ye L, et al. Tumour Biol. 2016 Jan;37(1):1151-7. doi: 10.1007/s13277-015-3835-y. Epub 2015 Aug 16. Tumour Biol. 2016. PMID: 26277787

4

MicroRNA-590-3p inhibits invasion and metastasis in triple-negative breast cancer by targeting Slug.

Yan M, Ye L, Feng X, Shi R, Sun Z, Li Z, Liu T. Yan M, et al. Among authors: ye l. Am J Cancer Res. 2020 Mar 1;10(3):965-974. eCollection 2020. Am J Cancer Res. 2020. PMID: 32266103 Free PMC article.

5

MiR-210 in exosomes derived from CAFs promotes non-small cell lung cancer migration and invasion through PTEN/PI3K/AKT pathway.

Yang F, Yan Y, Yang Y, Hong X, Wang M, Yang Z, Liu B, Ye L. Yang F, et al. Among authors: ye l. Cell Signal. 2020 Sep;73:109675. doi: 10.1016/j.cellsig.2020.109675. Epub 2020 May 21. Cell Signal. 2020. PMID: 32446904 Free article.

6

SASH1 suppresses triple-negative breast cancer cell invasion through YAP-ARHGAP42-actin axis.

Jiang K, Liu P, Xu H, Liang D, Fang K, Du S, Cheng W, Ye L, Liu T, Zhang X, Gong P, Shao S, Wang Y, Meng S. Jiang K, et al. Among authors: ye l. Oncogene. 2020 Jul;39(27):5015-5030. doi: 10.1038/s41388-020-1356-7. Epub 2020 Jun 10. Oncogene. 2020. PMID: 32523092

7

Combining Immune-Related Genes For Delineating the Extracellular Matrix and Predicting Hormone Therapy and Neoadjuvant Chemotherapy Benefits In Breast Cancer.

Liu J, Lei B, Yu X, Li Y, Deng Y, Yang G, Li Z, Liu T, Ye L. Liu J, et al. Among authors: ye l. Front Immunol. 2022 Jul 14;13:888339. doi: 10.3389/fimmu.2022.888339. eCollection 2022. Front Immunol. 2022. PMID: 35911730 Free PMC article.

8

FN1 mediated activation of aspartate metabolism promotes the progression of triple-negative and luminal a breast cancer.

Chen C, Ye L, Yi J, Liu T, Li Z. Chen C, et al. Among authors: ye l. Breast Cancer Res Treat. 2023 Oct;201(3):515-533. doi: 10.1007/s10549-023-07032-9. Epub 2023 Jul 17. Breast Cancer Res Treat. 2023. PMID: 37458908

9

Clinical Manifestation, Risk Factors, and Immune Checkpoint Inhibitor Rechallenge of Checkpoint Inhibitor-Associated Pneumonitis in Patients With Lung Cancer.

Li X, Yang F, Liu B, Ye L, Du J, Fan X, Yu Y, Li M, Bu L, Zhang Z, Xie L, Li W, Qi J. Li X, et al. Among authors: ye l. J Immunother. 2024 Jul-Aug 01;47(6):220-226. doi: 10.1097/CJI.0000000000000515. Epub 2024 Apr 11. J Immunother. 2024. PMID: 38618919

10

Autoantibodies against p16 protein-derived peptides may be a potential biomarker for non-small cell lung cancer.

Zhang C, Ye L, Guan S, Jin S, Wang W, Sun S, Lee KH, Wei J, Liu B. Zhang C, et al. Among authors: ye l. Tumour Biol. 2014 Mar;35(3):2047-51. doi: 10.1007/s13277-013-1271-4. Tumour Biol. 2014. PMID: 24122232

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8,629 results

Search Page

Filters